{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:35:08Z","timestamp":1791938108620,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0045"],"award-info":[{"award-number":["ANR-22-CE14-0045"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0045"],"award-info":[{"award-number":["ANR-22-CE14-0045"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Galectin-3 (Gal-3) expression is abnormally increased after renal ischemic injury, in various studies, further promoting tissue damage. Gal-3 may interact with the endothelial layer to induce inflammation during renal injury, linking the systemic and tissue compartments. However, this mechanism has not been investigated after acute kidney injury (AKI). To this end, wild-type (WT) and Gal-3-\/- mice underwent renal ischemia followed by reperfusion (rIR). Bone marrow transplantation was used to differentiate Gal-3 expression in renal tissue from systemic bone marrow cells. WT mice were injected with recombinant Gal-3 to study systemic issues. Gal-3 expression was assessed by immunofluorescence, western blot, and scRNAseq.\u00a0Systemic pathways were analyzed with plasma proteomics. Immunofluorescence and scRNAseq showed increased Gal-3 expression after rIR, in different tubular segments and infiltrating immune cells within damaged kidneys. In bone marrow transplanted mice, renal dysfunction, damage, and inflammation were higher when Gal-3 was expressed in renal tissue. Gal-3 upregulation was associated with endothelial activation and renal inflammation after rIR, both of which were prevented in Gal-3-\/- mice. Similar results were confirmed by plasma proteomics, as these mice showed reduced endothelial damage and rIR-associated inflammatory pathways. Systemic injection of recombinant Gal-3 increased the endothelial adhesion molecule CD146 expression in the kidney, without promoting renal injury. Interestingly, isolated renal tubules showed increased Gal-3 levels, interacting with CD146 to promote cytokine secretion and immune cell infiltration in the kidney. Thus, Gal-3 may promote endothelial activation via direct interaction with the endothelial activation marker CD146 after AKI, leading to renal injury and further systemic inflammation.<\/jats:p>","DOI":"10.1038\/s41598-025-25477-4","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:28:36Z","timestamp":1763987316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Galectin-3\/CD146 interaction promotes renal damage and systemic inflammation after acute kidney injury"],"prefix":"10.1038","volume":"15","author":[{"given":"L.","family":"Boutin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Piedagnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"D\u00e9pret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos E.","family":"Chadjichristos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"25477_CR1","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","volume":"41","author":"EAJ Hoste","year":"2015","unstructured":"Hoste, E. A. J. et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 41, 1411\u20131423 (2015).","journal-title":"Intensive Care Med."},{"key":"25477_CR2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.ackd.2018.08.004","volume":"25","author":"C Ronco","year":"2018","unstructured":"Ronco, C. & Bellasi, A. Di Lullo, L. Cardiorenal syndrome: an overview. Adv. Chronic Kidney Dis. 25, 382\u2013390 (2018).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"25477_CR3","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1056\/NEJMra1916393","volume":"382","author":"M Legrand","year":"2020","unstructured":"Legrand, M. & Rossignol, P. Cardiovascular consequences of acute kidney injury. N Engl. J. Med. 382, 2238\u20132247 (2020).","journal-title":"N Engl. J. Med."},{"key":"25477_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.kint.2016.03.043","volume":"90","author":"MLS Sequeira-Lopez","year":"2016","unstructured":"Sequeira-Lopez, M. L. S. & Torban, E. New insights into precursors of renal endothelium. Kidney Int. 90, 244\u2013246 (2016).","journal-title":"Kidney Int."},{"key":"25477_CR5","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3389\/fimmu.2018.01130","volume":"9","author":"H Cardinal","year":"2018","unstructured":"Cardinal, H., Dieud\u00e9, M. & H\u00e9bert, M. J. Endothelial dysfunction in kidney transplantation. Front. Immunol. 9, 1130 (2018).","journal-title":"Front. Immunol."},{"key":"25477_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jacbts.2019.06.005","volume":"4","author":"M Prud\u2019homme","year":"2019","unstructured":"Prud\u2019homme, M. et al. Acute kidney injury induces remote cardiac damage and dysfunction through the Galectin-3 pathway. JACC Basic. Transl Sci. 4, 717\u2013732 (2019).","journal-title":"JACC Basic. Transl Sci."},{"key":"25477_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.nephro.2021.07.304","volume":"17","author":"L Boutin","year":"2021","unstructured":"Boutin, L. et al. Impact of Galectin-3 tissue deletion in renal damage and type-3 cardio-renal syndrome. N\u00e9phrologie Th\u00e9rapeutique. 17, 284 (2021).","journal-title":"N\u00e9phrologie Th\u00e9rapeutique"},{"key":"25477_CR8","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.3390\/ijms23063124","volume":"23","author":"L Boutin","year":"2022","unstructured":"Boutin, L., D\u00e9pret, F., Gayat, E., Legrand, M. & Chadjichristos, C. E. Galectin-3 in kidney diseases: from an old protein to a new therapeutic target. Int. J. Mol. Sci. 23, 3124 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"25477_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-021-03878-x","volume":"26","author":"L Boutin","year":"2022","unstructured":"Boutin, L. et al. Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission. Crit. Care. 26, 1\u201312 (2022).","journal-title":"Crit. Care"},{"key":"25477_CR10","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00134-023-07198-2","volume":"49","author":"L Boutin","year":"2023","unstructured":"Boutin, L. et al. Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis. Intensive Care Med. 49, 1191\u20131202 (2023).","journal-title":"Intensive Care Med."},{"key":"25477_CR11","doi-asserted-by":"publisher","first-page":"F309","DOI":"10.1152\/ajprenal.00371.2021","volume":"322","author":"JC Oates","year":"2022","unstructured":"Oates, J. C., Russell, D. L. & Van Beusecum, J. P. Endothelial cells: potential novel regulators of renal inflammation. Am. J. Physiol. Ren. Physiol. 322, F309\u2013F321 (2022).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"25477_CR12","doi-asserted-by":"publisher","first-page":"F87","DOI":"10.1152\/ajprenal.00026.2003","volume":"285","author":"MJ Burne-Taney","year":"2003","unstructured":"Burne-Taney, M. J. et al. Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury. Am. J. Physiol. Ren. Physiol. 285, F87\u201394 (2003).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"25477_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2353\/ajpath.2008.070726","volume":"172","author":"NC Henderson","year":"2008","unstructured":"Henderson, N. C. et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288\u2013298 (2008).","journal-title":"Am. J. Pathol."},{"key":"25477_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ijms17040565","volume":"17","author":"SC Chen","year":"2016","unstructured":"Chen, S. C. & Kuo, P. L. The role of Galectin-3 in the kidneys. Int. J. Mol. Sci. 17, 565 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"25477_CR15","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/biom10091232","volume":"10","author":"S B\u00e4nfer","year":"2020","unstructured":"B\u00e4nfer, S. & Jacob, R. Galectins in Intra- and extracellular vesicles. Biomolecules 10, 1232 (2020).","journal-title":"Biomolecules"},{"key":"25477_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1432-2277.2008.00705.x","volume":"21","author":"AP Fernandes Bertocchi","year":"2008","unstructured":"Fernandes Bertocchi, A. P. et al. A role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl. Int. 21, 999\u20131007 (2008).","journal-title":"Transpl. Int."},{"key":"25477_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L","volume":"211","author":"C Colnot","year":"1998","unstructured":"Colnot, C., Fowlis, D., Ripoche, M. A., Bouchaert, I. & Poirier, F. Embryonic implantation in galectin 1\/galectin 3 double mutant mice. Dev. Dyn. 211, 306\u2013313 (1998).","journal-title":"Dev. Dyn."},{"key":"25477_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HYPERTENSIONAHA.115.06161","volume":"67","author":"G Vergaro","year":"2016","unstructured":"Vergaro, G. et al. Inhibition of Galectin-3 pathway prevents Isoproterenol-Induced left ventricular dysfunction and fibrosis in mice. Hypertension 67, 606\u2013612 (2016).","journal-title":"Hypertension"},{"key":"25477_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1681\/ASN.2018090912","volume":"30","author":"H Wu","year":"2019","unstructured":"Wu, H., Kirita, Y., Donnelly, E. L. & Humphreys, B. D. Advantages of Single-Nucleus over Single-Cell RNA sequencing of adult kidney: rare cell types and novel cell States revealed in fibrosis. J. Am. Soc. Nephrol. 30, 23\u201332 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"25477_CR20","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1073\/pnas.2005477117","volume":"117","author":"Y Kirita","year":"2020","unstructured":"Kirita, Y., Wu, H., Uchimura, K., Wilson, P. C. & Humphreys, B. D. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc. Natl. Acad. Sci. U S A. 117, 15874\u201315883 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"25477_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1681\/ASN.2021081150","volume":"33","author":"EE Dixon","year":"2022","unstructured":"Dixon, E. E., Wu, H., Muto, Y., Wilson, P. C. & Humphreys, B. D. Spatially resolved transcriptomic analysis of acute kidney injury in a female murine model. J. Am. Soc. Nephrol. 33, 279\u2013289 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"25477_CR22","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1074\/jbc.M117.783431","volume":"292","author":"F Colomb","year":"2017","unstructured":"Colomb, F. et al. Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. J. Biol. Chem. 292, 8381\u20138389 (2017).","journal-title":"J. Biol. Chem."},{"key":"25477_CR23","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1016\/j.molimm.2009.07.026","volume":"46","author":"CMW van Stijn","year":"2009","unstructured":"van Stijn, C. M. W. et al. Regulation of expression and secretion of galectin-3 in human monocyte-derived dendritic cells. Mol. Immunol. 46, 3292\u20133299 (2009).","journal-title":"Mol. Immunol."},{"key":"25477_CR24","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.tips.2023.06.001","volume":"44","author":"S Bouffette","year":"2023","unstructured":"Bouffette, S., Botez, I. & De Ceuninck, F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol. Sci. 44, 519\u2013531 (2023).","journal-title":"Trends Pharmacol. Sci."},{"key":"25477_CR25","first-page":"5033","volume":"53","author":"P Nangia-Makker","year":"1993","unstructured":"Nangia-Makker, P., Ochieng, J., Christman, J. K. & Raz, A. Regulation of the expression of galactoside-binding lectin during human monocytic differentiation. Cancer Res. 53, 5033\u20135037 (1993).","journal-title":"Cancer Res."},{"key":"25477_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2215\/CJN.12591117","volume":"13","author":"AS Go","year":"2018","unstructured":"Go, A. S. et al. Acute kidney injury and risk of heart failure and atherosclerotic events. Clin. J. Am. Soc. Nephrol. 13, 833\u2013841 (2018).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"25477_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00134-021-06454-7","volume":"47","author":"P Pickkers","year":"2021","unstructured":"Pickkers, P. et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med. 47, 835\u2013850 (2021).","journal-title":"Intensive Care Med."},{"key":"25477_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jcrc.2021.06.013","volume":"65","author":"H Sun","year":"2021","unstructured":"Sun, H. et al. A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury. J. Crit. Care. 65, 192\u2013199 (2021).","journal-title":"J. Crit. Care"},{"key":"25477_CR29","doi-asserted-by":"publisher","first-page":"e0166272","DOI":"10.1371\/journal.pone.0166272","volume":"11","author":"E Martinez-Martinez","year":"2016","unstructured":"Martinez-Martinez, E. et al. Galectin-3 Blockade reduces renal fibrosis in two normotensive experimental models of renal damage. PLoS One. 11, e0166272 (2016).","journal-title":"PLoS One"},{"key":"25477_CR30","doi-asserted-by":"publisher","first-page":"BSR20181803","DOI":"10.1042\/BSR20181803","volume":"38","author":"H Li","year":"2018","unstructured":"Li, H., Yang, S., Li, J. & Feng, J. Galectin 3 Inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity. Biosci. Rep. 38, BSR20181803 (2018).","journal-title":"Biosci. Rep."},{"key":"25477_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-021-03538-0","volume":"25","author":"H Sun","year":"2021","unstructured":"Sun, H. et al. Galectin-3 in septic acute kidney injury: a translational study. Crit. Care. 25, 1\u201311 (2021).","journal-title":"Crit. Care"},{"key":"25477_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12964-025-02148-5","volume":"23","author":"YW Guo","year":"2025","unstructured":"Guo, Y. W. et al. Platelet glycoprotein VI promotes folic acid-induced acute kidney injury through interaction with tubular epithelial cell-derived galectin-3. Cell. Commun. Signal. 23, 148 (2025).","journal-title":"Cell. Commun. Signal."},{"key":"25477_CR33","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1681\/ASN.2018020125","volume":"29","author":"H Wu","year":"2018","unstructured":"Wu, H. et al. Single-Cell transcriptomics of a human kidney allograft biopsy specimen defines a diverse inflammatory response. J. Am. Soc. Nephrol. 29, 2069\u20132080 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"25477_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00134-022-06925-5","volume":"49","author":"C Monard","year":"2023","unstructured":"Monard, C., Meersch-Dini, M. & Joannidis, M. When the kidneys hurt, the other organs suffer. Intensive Care Med. 49, 233\u2013236 (2023).","journal-title":"Intensive Care Med."},{"key":"25477_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/HYPERTENSIONAHA.118.11874","volume":"73","author":"E Mart\u00ednez-Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez-Mart\u00ednez, E. et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) axis in cardiac fibrosis and inflammation. Hypertension 73, 602\u2013611 (2019).","journal-title":"Hypertension"},{"key":"25477_CR36","doi-asserted-by":"publisher","first-page":"854501","DOI":"10.3389\/fcvm.2022.854501","volume":"9","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Clinical implications of plasma Galectin-3 in heart failure with preserved ejection fraction: A Meta-Analysis. Front. Cardiovasc. Med. 9, 854501 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"25477_CR37","doi-asserted-by":"crossref","unstructured":"Mierke, C. T. Role of the endothelium during tumor cell metastasis: is the endothelium a barrier or a promoter for cell invasion and metastasis? J. Biophys. 2008, 183516 (2008).","DOI":"10.1155\/2008\/183516"},{"key":"25477_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","volume":"15","author":"N Jourde-Chiche","year":"2019","unstructured":"Jourde-Chiche, N. et al. Endothelium structure and function in kidney health and disease. Nat. Rev. Nephrol. 15, 87\u2013108 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"25477_CR39","doi-asserted-by":"crossref","unstructured":"Pang, D., Hildebrand, D. & Bachoo, P. Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury. Cochrane Database Syst. Rev. CD006642 (2019).","DOI":"10.1002\/14651858.CD006642.pub3"},{"key":"25477_CR40","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1159\/000083890","volume":"99","author":"L Daniel","year":"2005","unstructured":"Daniel, L. et al. Tubular CD146 expression in nephropathies is related to chronic renal failure. Nephron Exp. Nephrol. 99, e105\u2013111 (2005).","journal-title":"Nephron Exp. Nephrol."},{"key":"25477_CR41","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/HYPERTENSIONAHA.119.14176","volume":"77","author":"A Abed","year":"2021","unstructured":"Abed, A. et al. Endothelial-Specific deletion of CD146 protects against experimental glomerulonephritis in mice. Hypertension 77, 1260\u20131272 (2021).","journal-title":"Hypertension"},{"key":"25477_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/ATVBAHA.108.183251","volume":"29","author":"N Bardin","year":"2009","unstructured":"Bardin, N. et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler. Thromb. Vasc Biol. 29, 746\u2013753 (2009).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"25477_CR43","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/srep01687","volume":"3","author":"H Duan","year":"2013","unstructured":"Duan, H. et al. Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. Sci. Rep. 3, 1687 (2013).","journal-title":"Sci. Rep."},{"key":"25477_CR44","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.carres.2008.08.038","volume":"344","author":"VV Glinsky","year":"2009","unstructured":"Glinsky, V. V. & Raz, A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr. Res. 344, 1788\u20131791 (2009).","journal-title":"Carbohydr. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25477-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25477-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T14:03:52Z","timestamp":1763993032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-25477-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["25477"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-25477-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures (see Material and Methods for summary) were approved by the appropriate ethical committees of the French National Institute for Health and Medical Research (INSERM) and the University of Paris, under the authority of the project license: APAFIS#30134-2020122315302748. All animal experiments were performed in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"41575"}}